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Treatment of human amniotic ells (UAC) with human interferon-or (Hu-IFN~t) or phorbol myristate acetate (PMA) re- 
suited in translocation of protein kinase C (PK-C) activity from the cytosol fraction to that of the membranes. Analysis 
of 32p incorporation i to phospholipid fractions and studies of alterations in fatty acid content for the major phospholi- 
pids of IFN-treated cells suggest that phospholipases C and A 2 are activated by Hu-IFN,t. Addition of neomycin (an 
inhibitor of pbospholipase C), as well as mepacrine (an inhibitor of phospholipase A2) to IFN-treated cells inhibited the 
antiviral activity of Hu-IFN~t in the vesicular stomatitis virus (VSV)-UAC system used. These observations indicate that 
(i) activation of PK-C and (ii) diacylglycerol formation, arachidonic acid and/or lysophosphatidylcholine rel ase are im- 
portant steps in the mechanism of action of IFN. 
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1. INTRODUCTION 
It has been suggested that the antiviral action of 
IFN may be mediated through its effect on PK-C 
[1]. Observations that different IFNs are capable 
of inducing an increase in the concentration of
diacylglycerol in human fibroblasts [2] and Daudi 
cells [3,4] support his hypothesis. In addition, a 
substantial increase in activity of PK-C was 
demonstrated in macrophages treated with recom- 
binant IFN-y [5]; intracellular translocation of 
PK-C and blocking of IFN-7-induced mRNA syn- 
thesis by PK-C inhibitors have also been reported 
[6]. Synthetic diacylglycerols were shown to be 
able to induce an IFN-like antiviral state [7]. 
Although it is generally accepted that tumor- 
promoting phorbol esters act by substituting for 
diacylglycerol, reducing the calcium requirement 
for PK-C [8], it has also been shown that un- 
saturated fatty acids (oleic acid and arachidonic 
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acid) can activate PK-C independently of Ca 2+ and 
phospholipids [9]. Since certain lysophospholipids, 
particularly l sophosphatidylcholine, ar  effective 
stimulators or inhibitors of PK-C [10], it has been 
proposed that PK-C is dually regulated [11]. One 
route is mediated by phospholipase C activation 
leading to diacylglycerol e evation, and the other 
by phospholipase A2 activation leading to eleva- 
tion of cis fatty acids or lysophospholipids. 
Thus, it was of interest to study the role of PK-C 
and phospholipases C and phospholipase A2 in the 
development of the Hu-IFN or-induced antiviral 
state. 
2. MATERIALS AND METHODS 
Human amniotic cells (from V. Sorrentino, University of 
Rome) were grown in monolayer cultures using Parker's 199 
medium or in suspension cultures using Eagle's medium both 
containing 10% fetal calf serum. 
Hu-IFNct (spec. act. 1.23 x 10 7 IU/mg protein) was a pro- 
duct of EGIS Pharmacochemical Works (Budapest). 2 mM 
PMA (4-phorbol 12-myristate 13-acetate, Sigma) in 0.2-ml por- 
tions was stored in dimethyl sulfoxide at -20°C and diluted in 
Dulbecco's phosphate-buffered saline (PBS) before use. 
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Neomycin B sulphate was purchased from SIFA and mepacrine 
(quinacrine) from Sigma. 
The Indiana strain of vesicular stomatitis virus (VSV) was 
plaque-purified and passaged atlow multiplicities in UAC cells. 
Phospholipid-dependent protein kinase C activity was 
measured in the cytosol and in detergent-solubilized membrane 
fraction according to Kikkawa et al. [12] as detailed in [13]. 
Total lipids were extracted according to Folch et al. [14]. To 
determine radioactivity incorporated into polyphosphatidylino- 
sitols, total lipids were separated on silica gel G plates (20 × 20, 
Merck) using firstly chloroform/methanol/ammonia (4.3 M) 
(36 : 26: 8, v/v) then n-propanol/ammonia (4.3M) (6: 3, v/v) in 
the same direction [15]. Detection of spots was performed by 
spraying with 0.050/0 1-aminonaphthalene-8-sulphonic acid n
50°70 methanol under UV light. Phosphatidylinositol, di- and 
triphosphatidylinositols were then placed in liquid scintillation 
vials and counted. For determination f radioactivity in other 
phospholipids, aliquots of total lipid extract were spotted onto 
silica gel G plates containing 1.50/0 magnesium acetate and 
developed according to Rauser et al. [16] using chloroform/ 
methanol/ammonium hydroxide (65:25:5, v/v) in the first 
dimension and chloroform/methanol/acetone/acetic id/ 
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Fig. 1. Time course of association of PK-C activity with plasma 
membrane. Suspension cultures of UAC cells in Eagle's MEM 
medium containing 10070 fetal calf serum were washed in 
phosphate-buffered saline (PBS). Cells (2 x l07) were then 
suspended in Eppendorf tubes containing 1 ml PBS and 
stimulated with either PMA (final concentration 20nM) or Hu- 
IFNa (final concentration 1000 U/ml). PMA (e,o), Hu-IFNot 
(a ,  A). Cells were maintained in a water bath at 37°C, 
removed at the intervals indicated and the PK-C activity of 
samples assayed as detailed in [13]. PK-C activity was defined 
as the value observed in the presence of CaC12 and lipids minus 
that in the presence of EGTA, being expressed in units of cpm 
3Zp incorporated/2 min per total volume of each cytosolic and 
membrane preparation. 
water (30: 10:40:10:5, v/v) in the second. Lipid fractions were 
then removed and counted. 
For analysis of the fatty acid content of phospholipids, total 
lipids were separated asdescribed [16], then lipid fractions were 
transferred to screw-capped vials and transmethylated in the 
presence of 5% HCI in absolute methanol at 80°C for 3 h. GLC 
of fatty acid methyl esters was performed on a Hitachi model 
263-80 gas chromatograph connected to a Hitachi M263 data 
processor. Separation was performed on 10°70 Carbowax 20M 
coated onto 100-200 mesh Supelcoport (Supelco, Bellefonte, 
CA). 
For virus replication assay, UAC cells were grown in 
*1. 
50 
40 
~c 30  
.o 
~ 20 
~o 10 
5o o 
~,~ ',. 
L~ 
O~ eLL 10 
LQ.  
O× V~ 
?, 
r~ 
r,  ,J 
r~ 
¢~ 
¢, 
PE  PC 
PI P IP  P IP  2 PA 
Fig.2. Effect of IFNc~ on 32p incorporation i to phospholipids 
of UAC cells. Samples of monolayer cultures of UAC cells (2 × 
107 cells/tissue culture flask) in Parker's 199 medium 
containing 2% fetal calf serum were stimulated with 1000 U/ml 
Hu-IFNa. After 12 h incubation, cells were washed in PBS and 
labelled with [32P]orthophosphate (40kBq/ml) for 3 h in 
Parker's 199 medium containing 2o70 fetal calf serum. Cells 
were then harvested and lipid extracts chromatographed as set 
out in section 2. Phosphatidylethanolamine (PE), phosphatidyl- 
choline (PC), phosphatidic a id (PA) and phosphatidylinositol 
bands (PI, PIP, PIP2) were excised from the thin-layer plates 
and the radioactivity determined by liquid scintillation 
counting. (Unfilled bars) Control samples, (hatched bars) IFN- 
treated samples. Mean of three experiments. 
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monolayer cultures and pretreated for 1 h with 1 mM neomycin 
or 5/zM mepacrine. After pretreatment, he medium was 
changed and cells were exposed for 18 h to 1000 IU/ml Hu- 
IFNa (0.2 ml) as well as to the initial concentrations of 
neomycin or mepacrine. Cultures were then thoroughly washed 
in PBS and VSV reproduction capacity examined by studying 
the cytopathic effect exerted on monolayer cultures of UAC 
cells in Microtest TC plates (Falcon) 18 h after virus infection, 
the results being expressed in 50% tissue culture infectious 
doses (TCIDso). 
3. RESULTS AND DISCUSSION 
Fig.1 shows that both Hu-IFNcr and PMA in- 
duce translocation of PK-C activity from the 
cytosol to the membrane fraction. It can also be 
seen that PMA-stimulated membrane association 
of PK-C is more rapid and of a higher intensity 
than that with IFN. These findings are consistent 
with our previous studies demonstrating an IFN- 
like antiviral effect of PMA [1]. 
Since PK-C is activated by diacylglycerol 
generated through the signal-dependent break- 
down of  inositol phospholipids induced by 
phospholipase C, the effect of Hu-IFNtr on 32p in- 
corporation into the phospholipids was studied. 
Fig.2 shows that stimulation of UAC cells with 
Hu- IFNa significantly increases 32p incorporation 
into phosphatidylinositol fractions and phosphati- 
dic acid. In contrast, 32p incorporation into the 
phosphatidylcholine and phosphatidylethanol- 
amine fractions was not altered. Thus, it can be 
concluded that IFN treatment has no effect on 
[32p]orthophosphate uptake but does increase the 
turnover of inositol phospholipids by activating 
phospholipase C. 
The effects of IFN on fatty acid content of all 
major phospholipids were also studied (table 1). 
IFN induced significant alterations in the fatty acid 
composition of phosphatidylinositol. These 
changes, in accordance with the results in fig.2, 
also support he conclusion that IFN treatment ac- 
tivates phospholipase C. No significant changes 
occurred in the major fatty acids of other 
phospholipids except for the altered arachidonic 
acid (20:4) content of phosphatidylcholine. This 
alteration cannot be explained on the basis of an 
increase in the activity of phospholipase C but in- 
dicates activation of phospholipase A2. 
To determine whether activation of phospho- 
lipases C and A2 is indeed involved in the genera- 
tion of the antiviral state induced by Hu-IFNa, 
inhibitors of these enzymes were employed. 
Neomycin is known to block the hydrolysis of 
phosphoinositides [17,18] and mepacrine has been 
reported to inhibit phospholipase A2 without af- 
fecting phospholipase C [19,20]. Fig.3 shows that 
neomycin inhibits the antiviral effect of IFN in a 
Table 1 
Fatty acid composition of phospholipids of control and IFN-treated human amnion cells 
Phospholipid Treatment Fatty acid (% of total) 
14:0 i.16:0 16:0 16:1 18:0 18:l 18:2 18:3 20:4 20:5 22:6 
Total phospholipid control 2.3 3.0 18.8 4.3 3.7 40.2 2.3 0.7 9.4 0.8 0.5 
IFN-treated 2.3 3.7 21.2 4.7 4.4 41.7 1.9 0.7 9.0 0.5 - 
Phosphatidylcholine control 3.6 1.0 28.8 5.0 0.6 47.5 1.3 0.3 3.5 0.5 0.7 
IFN-treated 4.0 1.2 30.9 6.0 0.4 46.4 1.3 0.3 1.7 0.3 0.3 
Phosphatidylethanolamine control 1.8 8.6 7.7 2.3 4.5 35.0 1.3 - 19.8 2.4 2.8 
IFN-treated 2.1 8.0 7.5 2.3 3.9 36.5 1.4 0.2 20.0 2.6 2.8 
Phosphatidylserine control - - 4.0 2.3 22.3 35.8 1.2 0.3 10.7 1.9 1.2 
IFN-treated - - 4.7 3.3 24.7 40.6 1.4 - 11.9 2.4 0.6 
Phosphatidylinositol control - - 17.3 6.6 4.0 20.2 0.8 - 7.0 0.5 0.6 
IFN-treated - - 9.3 2.3 2.1 40.4 1.8 0.3 16.2 2.4 4.0 
UAC cells (106/ml) suspended in Eagle's MEM containing 10070 fetal calf serum were grown overnight in magnetically stirred vessels. 
The medium was then replaced by Eagle's MEM containing 2% fetal calf serum; cell samples were then treated with 1000 IU/ml Hu- 
IFNo~ for 12 h and, after centrifugation at 2000 × g for 10 rain, cells (2 × 108/sample) were processed for lipid analysis (see section 
2). Identification fpeaks was performed using authentic standards. Errors in determinations were <2% and 5% for the major and 
minor fatty acids, respectively. Integrated peak areas of all fatty acids on the chromatogram were taken as the total (100%). 
Experiment performed 3 times, with the data being from a representative experiment 
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dose-dependent manner.  This result is in good 
agreement with f indings that the antiviral  activity 
o f  human IFNcr and ~' in human embryo 
f ibroblasts can be also blocked with neomycin [7]. 
A similar phenomenon was observed when 
mepacr ine was used (fig.3). Fig.3 depicts the 
results obtained in experiments where the effect of  
inhibitors proved to be maximal .  It should be 
stressed, however, that the inhibitory effects are 
dependent on the actual concentrat ion of  IFN 
used. Neomycin and mepacr ine were also effective 
when added 1 h after IFN (not shown), indicating 
that these agents do not act by blocking adsorpt ion 
of  I FN  to cell surface receptors. 
Apparent ly ,  the data obtained are in support  o f  
the hypothesis that act ivat ion of  PK-C is involved 
in generating the effects of  I FN  [21,22]. It was also 
demonstrated that t reatment of  UAC cells with 
IFNcr resulted in alterat ions in fatty acid content o f  
phosphol ip ids similar to those in the mouse IFNff- 
S-180 mouse sarcoma cell system [23]. Since addi-  
t ion o f  neomycin and mepacr ine part ia l ly  inhibits 
the antiviral  activity of  IFN,  it is reasonable to 
conclude that act ivat ion of  phosphol ipases C and 
A2 is involved in the action o f  IFN.  Since these en- 
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Fig.3. Effect of neom cin and mepacrine on the antiviral 
activity of Hu-IFNa. Results are presented as means of VSV 
yield/0.1 ml lOglo + SE for three experiments a  measured by 
the cytopathic effect (see section 2). (1) Control, VSV-infected 
UAC cells. VSV-infected cells pretreated with: (2) 1 mM 
neomycin; (3) 5/~M mepacrine; (4) 1000 IU/ml Hu-IFNa; (5) 
1000 IU/ml Hu-IFNot and 1 mM neomycin; (6) 1000 IU/ml 
Hu-IFNot and 5/~M mepacrine. 
zymes are associated with the format ion of  
diacylglycerol and release of  arachidonic acid 
and/or  lysophosphat idylchol ine,  the part ic ipat ion 
o f  the latter mechanisms in the action of  IFN,  as 
supposed in previous studies [2-4,24],  can be con- 
sidered to be most likely. 
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